Drug
Pegylated Recombinant Factor Viii
Pegylated Recombinant Factor Viii: highest development phase Phase 3, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| PEGylated Recombinant Factor VIII NCT02585960 | Phase 3 | Hemophilia A |
Latest
No recent events.
Follow Pegylated Recombinant Factor Viii on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.